BAC: 83/100 - Strong trend and structure, but overbought RSI and low volume cap confirmation.
XOM: 40/100 - No setup, mixed trend, downgrade catalyst offsets no earnings risk.
LLY: 85/100 - Good pullback entry with clear stop, but overbought conditions weaken confirmation.
MSFT: 89/100 - Best R:R (2.54) with strong trend and no gap risk; slight overbought daily.
PLTR: 55/100 - Bullish momentum but extended and no acceptable R:R; skip.
XRPUSD: 66/100 - Bearish break and decent R:R, but weak trend, regulatory overhang, and oversold bounce risk.
JPM: 45/100 - Ranging market, poor R:R, overbought; no trade.
ORCL: 79/100 - Bullish reversal but near resistance, overbought, and volume declining.
ESTX50: 45/100 - Overbought at resistance, no R:R, index lacks directional clarity.
ADBE: 35/100 - Mixed trend, terrible R:R near resistance; no valid setup.
Overall Winner: MSFT (89/100)
BAC BUY
Direction: BUY
Entry: $64.05 (limit)
Stop Loss: $63.00
Take Profit 1: $66.20 (+3.4%)
Take Profit 2: $67.50 (+5.4%)
R:R: 2.0
Position Size: 2.0% of account
Confidence: 65/100
Holding Period: 10 days
Key Levels
- Resistance: $64.00, $64.30, $65.00
- Support: $63.00, $62.60, $61.80
Rationale
Bullish trend confirmed by price above all major MAs, supertrend up, ADX 33 (strong trend). Q2 2026 earnings beat (EPS $1.21 vs $1.13 est) with strong revenue growth (+15% YoY), trading revenue up 33%, IB fees up 50%, and $6B buybacks; management expects NII recovery in H2 2026. Price is sitting just below the 52-week high (64.00), and a breakout above this level could extend the rally. The 1-hour timeframe shows price above VWAP and RSI 65, leaving room for upside. Earnings date (Oct 14, 2026) is outside the 10-day holding window, eliminating gap risk. tradingkey.com, barchart.com
Risks
- RSI on daily and weekly are near overbought (69.8 and 73.8), increasing pullback risk.
- Price is at the top of the Bollinger Band (%B=1.0) and 95% of the 10-day range, indicating extended conditions.
- Resistance at 64.00 (52-week high) may repel price leading to a false breakout.
- Low relative volume (RVOL 0.77) on the rally could signal weak conviction.
News Summary
Bank of America reported strong Q2 2026 results on July 14: EPS $1.21 beat by 7.7%, revenue $31.56B up 15% YoY, with trading revenue +33% and IB fees +50%. NII slightly missed but management expects improvement in H2. The stock broke above $60.51 resistance and is trading near $63.86, with next resistance at $64.00. Next earnings is Oct 14, 2026. Source: tradingview.com, barchart.com, fxleaders.com
{
"ticker": "BAC",
"direction": "LONG",
"entry_price": 64.05,
"stop_loss": 63.0,
"take_profit_1": 66.2,
"take_profit_2": 67.5,
"reward_risk_ratio": 2.05,
"position_size_pct": 2.0,
"confidence": 65,
"holding_period_days": 10,
"key_levels": {
"support": [
63.0,
62.6,
61.8
],
"resistance": [
64.0,
64.3,
65.0
]
},
"rationale": "Bullish trend confirmed by price above all major MAs, supertrend up, ADX 33 (strong trend). Q2 2026 earnings beat (EPS $1.21 vs $1.13 est) with strong revenue growth (+15% YoY), trading revenue up 33%, IB fees up 50%, and $6B buybacks; management expects NII recovery in H2 2026. Price is sitting just below the 52-week high (64.00), and a breakout above this level could extend the rally. The 1-hour timeframe shows price above VWAP and RSI 65, leaving room for upside. Earnings date (Oct 14, 2026) is outside the 10-day holding window, eliminating gap risk. [tradingkey.com](https://www.tradingkey.com/analysis/stocks/us-stocks/262034630-bank-of-america-bac-q2-2026-earnings-91b-profit-trading-breakout-63-tradingkey), [barchart.com](https://www.barchart.com/stocks/quotes/BAC/overview)",
"risks": [
"RSI on daily and weekly are near overbought (69.8 and 73.8), increasing pullback risk.",
"Price is at the top of the Bollinger Band (%B=1.0) and 95% of the 10-day range, indicating extended conditions.",
"Resistance at 64.00 (52-week high) may repel price leading to a false breakout.",
"Low relative volume (RVOL 0.77) on the rally could signal weak conviction."
],
"news_summary": "Bank of America reported strong Q2 2026 results on July 14: EPS $1.21 beat by 7.7%, revenue $31.56B up 15% YoY, with trading revenue +33% and IB fees +50%. NII slightly missed but management expects improvement in H2. The stock broke above $60.51 resistance and is trading near $63.86, with next resistance at $64.00. Next earnings is Oct 14, 2026. Source: [tradingview.com](https://www.tradingview.com/symbols/NYSE-BAC/), [barchart.com](https://www.barchart.com/stocks/quotes/BAC/technical-analysis), [fxleaders.com](https://www.fxleaders.com/news/2026/07/15/bank-of-america-bac-stock-price-forecast-bac-breaks-above-60-as-strong-q2-earnings-lift-outlook/)"
}
XOM
Confidence: 60/100
Key Levels
- Resistance: $160.37, $163.68, $175.22
- Support: $149.09, $142.03, $134.95
Rationale
Daily trend is mixed/consolidating (ADX 20.3, price stuck in range). Price sits just below 10d/20d resistance at 160.37 after a 4.4% surge, but 1H RSI (70.5) and StochRSI are overbought. J.P. Morgan downgraded XOM to Hold with a $158 target below the current price, adding a bearish catalyst. No confirmed reversal setup exists to justify shorting, and reward:risk for a long entry at current price is insufficient (nearest support is far, requiring a wide stop). With the stock at resistance and overbought, the setup does not meet the required 2:1 reward:risk ratio.
Risks
- Breakout above 160.37 could trigger a strong move, but overbought conditions increase pullback risk
- Downgrade by J.P. Morgan to Hold with $158 target suggests limited upside potential
- Consolidation phase with ADX < 25 indicates weak trend, making false breakouts likely
- Broad market volatility (VIX 15.5) could impact oil price and XOM despite earnings being far away
News Summary
Next earnings are Oct 23/30, 2026 (far outside 10-day window). Latest quarterly EPS was $3.52 vs $3.56 estimate. J.P. Morgan downgraded XOM to Hold and raised target to $158. Weekly forecast sees price range $150.63-$159.78 with resistance at $158.7; current price ($159.79) has broken above that, but overbought indicators (RSI/Stoch) warn of exhaustion. tradersunion.com tradingdashboard.com tradingview.com
{
"ticker": "XOM",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 60,
"holding_period_days": null,
"key_levels": {
"support": [
149.09,
142.03,
134.95
],
"resistance": [
160.37,
163.68,
175.22
]
},
"rationale": "Daily trend is mixed/consolidating (ADX 20.3, price stuck in range). Price sits just below 10d/20d resistance at 160.37 after a 4.4% surge, but 1H RSI (70.5) and StochRSI are overbought. J.P. Morgan downgraded XOM to Hold with a $158 target below the current price, adding a bearish catalyst. No confirmed reversal setup exists to justify shorting, and reward:risk for a long entry at current price is insufficient (nearest support is far, requiring a wide stop). With the stock at resistance and overbought, the setup does not meet the required 2:1 reward:risk ratio.",
"risks": [
"Breakout above 160.37 could trigger a strong move, but overbought conditions increase pullback risk",
"Downgrade by J.P. Morgan to Hold with $158 target suggests limited upside potential",
"Consolidation phase with ADX < 25 indicates weak trend, making false breakouts likely",
"Broad market volatility (VIX 15.5) could impact oil price and XOM despite earnings being far away"
],
"news_summary": "Next earnings are Oct 23/30, 2026 (far outside 10-day window). Latest quarterly EPS was $3.52 vs $3.56 estimate. J.P. Morgan downgraded XOM to Hold and raised target to $158. Weekly forecast sees price range $150.63-$159.78 with resistance at $158.7; current price ($159.79) has broken above that, but overbought indicators (RSI/Stoch) warn of exhaustion. [tradersunion.com](https://tradersunion.com/news/stocks/show/2804982-exxon-mobil-slips-1-11percent-this/) [tradingdashboard.com](https://tradingdashboard.com/en/stocks/XOM-NYSE) [tradingview.com](https://www.tradingview.com/symbols/NYSE-XOM/)"
}
LLY BUY
Direction: BUY
Entry: $1,190.00 (limit)
Stop Loss: $1,168.00
Take Profit 1: $1,234.00 (+3.7%)
Take Profit 2: $1,249.00 (+5.0%)
R:R: 2.0
Position Size: 2.0% of account
Confidence: 65/100
Holding Period: 10 days
Key Levels
- Resistance: $1,232.00, $1,249.45, $1,315.00
- Support: $1,188.00, $1,168.00, $1,141.00
Rationale
LLY is in a longer-term uptrend (price above all major moving averages, weekly RSI 65.7) but is currently overbought on the 1H chart (RSI 78, StochRSI 100) and after a +3.9% day is testing major resistance at $1,231.94 (10d/20d high). Daily ATR is $42.65; the nearest structural support zone is $1,168–$1,190 per ChartMill and TradersUnion. We plan a limit buy at $1,190 (upper end of support) with a stop at $1,168 (below the structural support) and initial target at $1,234 (just above resistance) for a 2:1 R:R. The second target at $1,249.45 (60d high) provides a 2.68:1 R:R. The pullback is consistent with the base case scenario of consolidation/progress in the $1,176–$1,315 range. Earnings on Oct 29, 2026 are far outside the 10-day holding window, eliminating gap risk. Technical indicators (weekly ADX 30.24, daily RSI 60.7) still support upside, but the immediate overbought conditions warrant an entry at support rather than chasing.
Risks
- Price may not pull back to $1,190, leaving the limit order unfilled.
- A break below $1,168 would invalidate the trade and lead to a loss.
- Overbought daily stochastics and weak ADX (19.3) could lead to a prolonged consolidation.
- Macro volatility (VIX 15.51) or unexpected news could trigger a sharp move against the position.
News Summary
Next earnings is Oct 29, 2026, with no gap risk in the 10-day window (TradingView). Recent news highlights strong demand for Mounjaro/Zepbound, new launches (Foundayo), and Alzheimer's drug Kisunla, while retatrutide filing was postponed to 2027 (TradersUnion). Technical analysis shows resistance at $1,231–$1,236 and support at $1,188–$1,190, with weekly forecast suggesting a high probability of trading in the $1,176–$1,315 range (TrendSpider, Meyka, ChartMill).
{
"ticker": "LLY",
"direction": "LONG",
"entry_price": 1190.0,
"stop_loss": 1168.0,
"take_profit_1": 1234.0,
"take_profit_2": 1249.0,
"reward_risk_ratio": 2.0,
"position_size_pct": 2.0,
"confidence": 65,
"holding_period_days": 10,
"key_levels": {
"support": [
1188.0,
1168.0,
1141.0
],
"resistance": [
1232.0,
1249.45,
1315.0
]
},
"rationale": "LLY is in a longer-term uptrend (price above all major moving averages, weekly RSI 65.7) but is currently overbought on the 1H chart (RSI 78, StochRSI 100) and after a +3.9% day is testing major resistance at $1,231.94 (10d/20d high). Daily ATR is $42.65; the nearest structural support zone is $1,168–$1,190 per [ChartMill](https://www.chartmill.com/stock/quote/LLY/technical-analysis) and [TradersUnion](https://tradersunion.com/news/stocks/show/2833521-eli-lilly-gains-2-03percent-this/). We plan a limit buy at $1,190 (upper end of support) with a stop at $1,168 (below the structural support) and initial target at $1,234 (just above resistance) for a 2:1 R:R. The second target at $1,249.45 (60d high) provides a 2.68:1 R:R. The pullback is consistent with the base case scenario of consolidation/progress in the $1,176–$1,315 range. Earnings on Oct 29, 2026 are far outside the 10-day holding window, eliminating gap risk. Technical indicators (weekly ADX 30.24, daily RSI 60.7) still support upside, but the immediate overbought conditions warrant an entry at support rather than chasing.",
"risks": [
"Price may not pull back to $1,190, leaving the limit order unfilled.",
"A break below $1,168 would invalidate the trade and lead to a loss.",
"Overbought daily stochastics and weak ADX (19.3) could lead to a prolonged consolidation.",
"Macro volatility (VIX 15.51) or unexpected news could trigger a sharp move against the position."
],
"news_summary": "Next earnings is Oct 29, 2026, with no gap risk in the 10-day window ([TradingView](https://www.tradingview.com/symbols/NYSE-LLY/)). Recent news highlights strong demand for Mounjaro/Zepbound, new launches (Foundayo), and Alzheimer's drug Kisunla, while retatrutide filing was postponed to 2027 ([TradersUnion](https://tradersunion.com/news/stocks/show/2833521-eli-lilly-gains-2-03percent-this/)). Technical analysis shows resistance at $1,231–$1,236 and support at $1,188–$1,190, with weekly forecast suggesting a high probability of trading in the $1,176–$1,315 range ([TrendSpider](https://trendspider.com/markets/symbols/LLY/), [Meyka](https://meyka.com/stock/LLY/technical-analysis/), [ChartMill](https://www.chartmill.com/stock/quote/LLY/technical-analysis))."
}
MSFT BUY
Direction: BUY
Entry: $498.50 (limit)
Stop Loss: $492.00
Take Profit 1: $515.00 (+3.3%)
Take Profit 2: $525.00 (+5.3%)
R:R: 2.5
Position Size: 1.5% of account
Confidence: 65/100
Holding Period: 8 days
Key Levels
- Resistance: $513.73, $516.08
- Support: $492.36, $490.47, $487.46
Rationale
MSFT is in a strong uptrend after stellar Q4 FY2026 earnings (Azure +43%, EPS $4.81), with price above all key moving averages. Daily RSI is overbought (~79) but 1H StochRSI is oversold, suggesting a short-term pullback toward the $495-500 support zone (Kijun and prior breakout). A limit entry around $498.50 with a stop below $492 (just under Kijun at $490.47) offers a 2.54:1 reward-to-risk to the first target at $515 (near the upper range of the expected trading band $492.36-$516.08) and further upside to $525. Next earnings is 78 days away, so no gap risk. Web search confirms momentum and levels: tradersunion.com, fxleaders.com, morningstar.com.
Risks
- Daily RSI and StochRSI are extremely overbought; a deeper pullback could occur before our limit fills.
- If price loses support at $487.46, the bullish structure would be compromised and the stop could be hit.
- Low volume (RVOL <0.8) suggests the rally may lack conviction, increasing the chance of range-bound action.
News Summary
Microsoft reported strong Q4 FY2026 results on July 30: revenue $90B (+17% YoY), Azure growth 43%, EPS $4.81. Stock jumped ~15% and has continued higher. Analysts expect short-term consolidation between $492.36 and $516.08. No imminent catalysts before late October; next earnings scheduled for 2026-10-28. Sources: investors.com, tradersunion.com.
{
"ticker": "MSFT",
"direction": "LONG",
"entry_price": 498.5,
"stop_loss": 492.0,
"take_profit_1": 515.0,
"take_profit_2": 525.0,
"reward_risk_ratio": 2.54,
"position_size_pct": 1.5,
"confidence": 65,
"holding_period_days": 8,
"key_levels": {
"support": [
492.36,
490.47,
487.46
],
"resistance": [
513.73,
516.08
]
},
"rationale": "MSFT is in a strong uptrend after stellar Q4 FY2026 earnings (Azure +43%, EPS $4.81), with price above all key moving averages. Daily RSI is overbought (~79) but 1H StochRSI is oversold, suggesting a short-term pullback toward the $495-500 support zone (Kijun and prior breakout). A limit entry around $498.50 with a stop below $492 (just under Kijun at $490.47) offers a 2.54:1 reward-to-risk to the first target at $515 (near the upper range of the expected trading band $492.36-$516.08) and further upside to $525. Next earnings is 78 days away, so no gap risk. Web search confirms momentum and levels: [tradersunion.com](https://tradersunion.com/news/stocks/show/2935725-microsoft-up-1-15percent-today-on/), [fxleaders.com](https://www.fxleaders.com/news/2026/07/30/why-is-microsoft-msft-stock-up-today-azure-grows-43-eps-hits-4-81/), [morningstar.com](https://www.morningstar.com/stocks/after-earnings-is-microsoft-stock-buy-sell-or-fairly-valued-11).",
"risks": [
"Daily RSI and StochRSI are extremely overbought; a deeper pullback could occur before our limit fills.",
"If price loses support at $487.46, the bullish structure would be compromised and the stop could be hit.",
"Low volume (RVOL <0.8) suggests the rally may lack conviction, increasing the chance of range-bound action."
],
"news_summary": "Microsoft reported strong Q4 FY2026 results on July 30: revenue $90B (+17% YoY), Azure growth 43%, EPS $4.81. Stock jumped ~15% and has continued higher. Analysts expect short-term consolidation between $492.36 and $516.08. No imminent catalysts before late October; next earnings scheduled for 2026-10-28. Sources: [investors.com](https://www.investors.com/research/microsoft-msft-stock-earnings-buy-now-august-2026/), [tradersunion.com](https://tradersunion.com/news/stocks/show/2935725-microsoft-up-1-15percent-today-on/)."
}
PLTR
Confidence: 70/100
Key Levels
- Resistance: $179.60, $207.52
- Support: $155.92, $152.25
Rationale
Price is overbought (RSI 73.9) and extended, trading near the top of its 10-day range and just 2.5% below key resistance at $179.60. A long at current levels would require a stop loss of at least 1x ATR ($8.95) to achieve a 2:1 reward/risk, putting targets above $193 — a move unlikely within the 10-day window given the overbought conditions and nearby resistance. Shorting is not permitted without a confirmed reversal setup, which is absent. Next earnings (Nov 2) is outside the holding window, so gap risk is low, but the risk/reward is unattractive. Waiting for a pullback to $156–158 support or a breakout above $180 with volume would offer a better entry.
Risks
- Overbought conditions may lead to a sharp pullback
- Extreme valuation at ~103x forward P/E leaves little room for error
- Momentum could continue, causing a missed opportunity
- Heavy insider selling has been noted in recent filings
News Summary
PLTR reported record Q2 2026 revenue of $1.935B (+93% YoY) and adjusted EPS of $0.41 (vs $0.33 estimate), while raising FY2026 guidance well above consensus. The stock surged ~29% on Aug 4 and continued higher, now at $175.23. Analysts have raised price targets (Deutsche Bank $200, Oppenheimer $200, Wedbush $230, DA Davidson $200), but technicals show overbought RSI (73.9) and price is near resistance. Next earnings is Nov 2, 2026 — outside the 10-day holding window. Sources: barchart.com, trendspider.com, tradersunion.com, daytraders.com.
{
"ticker": "PLTR",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 70,
"holding_period_days": null,
"key_levels": {
"support": [
155.92,
152.25
],
"resistance": [
179.6,
207.52
]
},
"rationale": "Price is overbought (RSI 73.9) and extended, trading near the top of its 10-day range and just 2.5% below key resistance at $179.60. A long at current levels would require a stop loss of at least 1x ATR ($8.95) to achieve a 2:1 reward/risk, putting targets above $193 — a move unlikely within the 10-day window given the overbought conditions and nearby resistance. Shorting is not permitted without a confirmed reversal setup, which is absent. Next earnings (Nov 2) is outside the holding window, so gap risk is low, but the risk/reward is unattractive. Waiting for a pullback to $156–158 support or a breakout above $180 with volume would offer a better entry.",
"risks": [
"Overbought conditions may lead to a sharp pullback",
"Extreme valuation at ~103x forward P/E leaves little room for error",
"Momentum could continue, causing a missed opportunity",
"Heavy insider selling has been noted in recent filings"
],
"news_summary": "PLTR reported record Q2 2026 revenue of $1.935B (+93% YoY) and adjusted EPS of $0.41 (vs $0.33 estimate), while raising FY2026 guidance well above consensus. The stock surged ~29% on Aug 4 and continued higher, now at $175.23. Analysts have raised price targets (Deutsche Bank $200, Oppenheimer $200, Wedbush $230, DA Davidson $200), but technicals show overbought RSI (73.9) and price is near resistance. Next earnings is Nov 2, 2026 — outside the 10-day holding window. Sources: [barchart.com](https://www.barchart.com/story/news/3669764/palantir-has-broken-above-its-200-day-moving-average-here-s-why-the-momentum-looks-sustainable), [trendspider.com](https://trendspider.com/markets/symbols/PLTR/), [tradersunion.com](https://tradersunion.com/news/stocks/show/2935432-palantir-jumps-5-32percent-after-record/), [daytraders.com](https://daytraders.com/news/2026/08/05/whats-going-on-with-palantir-stock-on-wednesday)."
}
XRPUSD SELL
Direction: SELL
Entry: $1.01 (limit)
Stop Loss: $1.05
Take Profit 1: $0.92 (+8.9%)
Take Profit 2: $0.90 (+10.9%)
R:R: 2.2
Position Size: 2.0% of account
Confidence: 60/100
Holding Period: 10 days
Key Levels
- Resistance: $1.05, $1.09, $1.14, $1.25
- Support: $1.00, $0.98, $0.92
Rationale
Short setup confirmed by break of the $1.05 descending-triangle support and daily closes below $1.02 on rising volume, with price below all key EMAs and a death cross. RSI at 34.1 and falling, ADX 15.8 (ranging but bearish bias), CMF -0.29 showing distribution. The measured move targets $0.92, and the Senate's delay of the Clarity Act removes a bullish catalyst (decrypt.co). Whale accumulation noted but no reversal confirmation; immediate support at $1.00, then $0.98 and $0.92 (phemex.com, decrypt.co).
Risks
- Strong psychological support at $1.00 could trigger a bounce
- Whale accumulation might underpin price and cause a short squeeze
- Low ADX indicates choppy/ranging conditions, reducing trend reliability
- Regulatory headlines could cause sudden volatility
- Oversold conditions (1H RSI 30.2) may lead to a technical rebound
News Summary
Senate punted on the Clarity Act, delaying regulatory clarity for XRP; XRP broke $1.05 support, with next support at $1.00; whales are accumulating but the trend remains bearish with a death cross; no scheduled catalyst in the next 10 days. Sources: decrypt.co, phemex.com, decrypt.co.
{
"ticker": "XRP-USD",
"direction": "SHORT",
"entry_price": 1.01,
"stop_loss": 1.05,
"take_profit_1": 0.92,
"take_profit_2": 0.9,
"reward_risk_ratio": 2.25,
"position_size_pct": 2.0,
"confidence": 60,
"holding_period_days": 10,
"key_levels": {
"support": [
1.0,
0.98,
0.92
],
"resistance": [
1.05,
1.09,
1.14,
1.25
]
},
"rationale": "Short setup confirmed by break of the $1.05 descending-triangle support and daily closes below $1.02 on rising volume, with price below all key EMAs and a death cross. RSI at 34.1 and falling, ADX 15.8 (ranging but bearish bias), CMF -0.29 showing distribution. The measured move targets $0.92, and the Senate's delay of the Clarity Act removes a bullish catalyst ([decrypt.co](https://decrypt.co/375136/xrp-price-crossroads-senate-punts-clarity-act)). Whale accumulation noted but no reversal confirmation; immediate support at $1.00, then $0.98 and $0.92 ([phemex.com](https://phemex.com/blogs/xrp-price-today-1-05-floor-break), [decrypt.co](https://decrypt.co/375051/xrp-bitcoin-whales-accumulating-bear-market)).",
"risks": [
"Strong psychological support at $1.00 could trigger a bounce",
"Whale accumulation might underpin price and cause a short squeeze",
"Low ADX indicates choppy/ranging conditions, reducing trend reliability",
"Regulatory headlines could cause sudden volatility",
"Oversold conditions (1H RSI 30.2) may lead to a technical rebound"
],
"news_summary": "Senate punted on the Clarity Act, delaying regulatory clarity for XRP; XRP broke $1.05 support, with next support at $1.00; whales are accumulating but the trend remains bearish with a death cross; no scheduled catalyst in the next 10 days. Sources: [decrypt.co](https://decrypt.co/375136/xrp-price-crossroads-senate-punts-clarity-act), [phemex.com](https://phemex.com/blogs/xrp-price-today-1-05-floor-break), [decrypt.co](https://decrypt.co/375051/xrp-bitcoin-whales-accumulating-bear-market)."
}
JPM
Confidence: 80/100
Key Levels
- Resistance: $363.00
- Support: $343.78, $325.75
Rationale
Price is trading just below strong resistance at $363.00 (52-week high), with the daily ADX at 14.4 indicating a ranging market and no clear trend. Weekly RSI is overbought at 72.1, and the weekly forecast expects consolidation between $345.42 and $359.05. A long entry would require a stop below $356.30 (recent swing low) or tighter, but the nearest target for a 2:1 reward-to-risk ratio would be above $366, which is above the established resistance and lacks confirmation. A short is not justified as the stock remains above all major moving averages and the macro trend is bullish. No acceptable setup exists with the required risk/reward, so the trade is skipped.
Risks
- Breakout above $363.00 could trigger a momentum rally, missing a potential long entry.
- Overbought daily and weekly RSI could lead to a sharp pullback if selling pressure emerges.
- Low volume and thinning participation (RVOL 0.67x) reduce conviction in directional moves.
News Summary
JPM reported record Q2 earnings with net income of $16.9B and approved a dividend increase to $1.65 per share (tradersunion.com). Technical indicators show overbought conditions on weekly RSI and CCI, with consolidation expected between $345.42 and $359.05 (techi.com). The stock trades above its 50-day and 200-day moving averages, and next earnings are on October 13, 2026, well outside the 10-day window (mystockharbor.com).
{
"ticker": "JPM",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 80,
"holding_period_days": null,
"key_levels": {
"support": [
343.78,
325.75
],
"resistance": [
363.0
]
},
"rationale": "Price is trading just below strong resistance at $363.00 (52-week high), with the daily ADX at 14.4 indicating a ranging market and no clear trend. Weekly RSI is overbought at 72.1, and the weekly forecast expects consolidation between $345.42 and $359.05. A long entry would require a stop below $356.30 (recent swing low) or tighter, but the nearest target for a 2:1 reward-to-risk ratio would be above $366, which is above the established resistance and lacks confirmation. A short is not justified as the stock remains above all major moving averages and the macro trend is bullish. No acceptable setup exists with the required risk/reward, so the trade is skipped.",
"risks": [
"Breakout above $363.00 could trigger a momentum rally, missing a potential long entry.",
"Overbought daily and weekly RSI could lead to a sharp pullback if selling pressure emerges.",
"Low volume and thinning participation (RVOL 0.67x) reduce conviction in directional moves."
],
"news_summary": "JPM reported record Q2 earnings with net income of $16.9B and approved a dividend increase to $1.65 per share ([tradersunion.com](https://tradersunion.com/news/stocks/show/2833335-jpmorgan-slips-0-93percent-over-the/)). Technical indicators show overbought conditions on weekly RSI and CCI, with consolidation expected between $345.42 and $359.05 ([techi.com](https://www.techi.com/quote/JPM/technicals/)). The stock trades above its 50-day and 200-day moving averages, and next earnings are on October 13, 2026, well outside the 10-day window ([mystockharbor.com](https://www.mystockharbor.com/stock/JPM))."
}
ORCL BUY
Direction: BUY
Entry: $151.05 (limit)
Stop Loss: $143.40
Take Profit 1: $166.35 (+10.1%)
Take Profit 2: $175.00 (+15.9%)
R:R: 2.0
Position Size: 2.0% of account
Confidence: 65/100
Holding Period: 10 days
Key Levels
- Resistance: $151.99, $153.49, $166.35, $175.00
- Support: $143.47, $140.69, $139.03
Rationale
Daily trend is bullish (price above EMA50/EMA21, Supertrend UP, ADX 28.5, MACD rising). Price has broken above the lower swing high of $149.07, confirming a bullish reversal after testing long-term support near $118.86 as noted by fxempire.com. The next earnings is on 2026-09-08/10, outside the 10-day holding window, so gap risk is low. The recent rally is supported by strong Q4 results and maintained guidance per flipsidefinance.com. Entry at current price with stop below the recent swing low of 143.47 (within 1x ATR of 7.43), target 1 gives exactly 2:1 reward/risk. Position size per risk rules set to 2%.
Risks
- Price is near resistance at 151.99 and within the supply zone $148–$264 from flipsidefinance.com, which could stall the rally.
- StochRSI is extremely overbought (97.74), and volume has been declining on up days, suggesting weak conviction.
- Implied volatility is elevated (IV percentile 88%), indicating possible large swings that could trigger stop loss.
- A broader market downturn or negative surprise could weigh on the stock despite low gap risk from earnings.
News Summary
Oracle reported fiscal Q4 2026 EPS of $2.11 vs consensus $1.96 and revenue of $19.18B (+20.6% YoY), with management maintaining FY2026 revenue and capex guidance (source: flipsidefinance.com). The stock has rallied sharply from oversold conditions after testing long-term support near $118.86, with a bullish reversal signal confirmed above $149.07 (source: fxempire.com). Next earnings is scheduled for September 8-10, 2026, outside the 10-day holding window. Technical levels from barchart.com indicate immediate resistance at $151.99, and support at $143.85.
{
"ticker": "ORCL",
"direction": "LONG",
"entry_price": 151.05,
"stop_loss": 143.4,
"take_profit_1": 166.35,
"take_profit_2": 175.0,
"reward_risk_ratio": 2.0,
"position_size_pct": 2.0,
"confidence": 65,
"holding_period_days": 10,
"key_levels": {
"support": [
143.47,
140.69,
139.03
],
"resistance": [
151.99,
153.49,
166.35,
175.0
]
},
"rationale": "Daily trend is bullish (price above EMA50/EMA21, Supertrend UP, ADX 28.5, MACD rising). Price has broken above the lower swing high of $149.07, confirming a bullish reversal after testing long-term support near $118.86 as noted by [fxempire.com](https://www.fxempire.com/forecasts/article/oracle-corp-orcl-price-forecast-can-oversold-conditions-fuel-a-powerful-rebound-1611890). The next earnings is on 2026-09-08/10, outside the 10-day holding window, so gap risk is low. The recent rally is supported by strong Q4 results and maintained guidance per [flipsidefinance.com](https://flipsidefinance.com/assets/oracle-orcl). Entry at current price with stop below the recent swing low of 143.47 (within 1x ATR of 7.43), target 1 gives exactly 2:1 reward/risk. Position size per risk rules set to 2%.",
"risks": [
"Price is near resistance at 151.99 and within the supply zone $148–$264 from [flipsidefinance.com](https://flipsidefinance.com/assets/oracle-orcl), which could stall the rally.",
"StochRSI is extremely overbought (97.74), and volume has been declining on up days, suggesting weak conviction.",
"Implied volatility is elevated (IV percentile 88%), indicating possible large swings that could trigger stop loss.",
"A broader market downturn or negative surprise could weigh on the stock despite low gap risk from earnings."
],
"news_summary": "Oracle reported fiscal Q4 2026 EPS of $2.11 vs consensus $1.96 and revenue of $19.18B (+20.6% YoY), with management maintaining FY2026 revenue and capex guidance (source: [flipsidefinance.com](https://flipsidefinance.com/assets/oracle-orcl)). The stock has rallied sharply from oversold conditions after testing long-term support near $118.86, with a bullish reversal signal confirmed above $149.07 (source: [fxempire.com](https://www.fxempire.com/forecasts/article/oracle-corp-orcl-price-forecast-can-oversold-conditions-fuel-a-powerful-rebound-1611890)). Next earnings is scheduled for September 8-10, 2026, outside the 10-day holding window. Technical levels from [barchart.com](https://www.barchart.com/stocks/quotes/ORCL) indicate immediate resistance at $151.99, and support at $143.85."
}
ESTX50
Confidence: 70/100
Key Levels
- Resistance: $6,559.99
- Support: $6,235.78, $6,194.39, $5,842.18
Rationale
Price is within 0.3% of the 10/20/60-day resistance at 6559.99 and trading at the top of its 10-day range (93%). Daily StochRSI is extremely overbought (K/D: 100/99.38) while RSI is at 69. ATR(14) is 66.09 (1.01%), but the proximity to resistance leaves no room for a 2:1 reward-to-risk long entry without risking a breakout failure. No confirmed reversal setup exists for a short, and the daily trend remains bullish (price above 200 SMA and Supertrend UP). After web search verification, no earnings or high-impact catalysts are scheduled in the next 10 sessions, but the index is in consolidation with no clean directional signal. Thus, no acceptable setup meets the risk/reward and trend requirements.
Risks
- Potential breakout above 6559.99 could lead to an extended move, but entry risk is unfavorable.
- Overbought StochRSI and proximity to resistance increase risk of pullback.
- Low volume (RVOL 0.00x) suggests absence of strong momentum confirmation.
News Summary
Web search on 2026-08-11 confirms the Euro Stoxx 50 is in an uptrend, trading above its 200-day moving average with strong buy signals from multiple moving averages (investing.com). Forecast models indicate range-bound behavior with expected moves of ±1.8% over 14 days and no directional clarity (sigmanomics.com). No earnings or major scheduled catalysts were found for the index within the holding window.
{
"ticker": "^STOXX50E",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 70,
"holding_period_days": null,
"key_levels": {
"support": [
6235.78,
6194.39,
5842.18
],
"resistance": [
6559.99
]
},
"rationale": "Price is within 0.3% of the 10/20/60-day resistance at 6559.99 and trading at the top of its 10-day range (93%). Daily StochRSI is extremely overbought (K/D: 100/99.38) while RSI is at 69. ATR(14) is 66.09 (1.01%), but the proximity to resistance leaves no room for a 2:1 reward-to-risk long entry without risking a breakout failure. No confirmed reversal setup exists for a short, and the daily trend remains bullish (price above 200 SMA and Supertrend UP). After web search verification, no earnings or high-impact catalysts are scheduled in the next 10 sessions, but the index is in consolidation with no clean directional signal. Thus, no acceptable setup meets the risk/reward and trend requirements.",
"risks": [
"Potential breakout above 6559.99 could lead to an extended move, but entry risk is unfavorable.",
"Overbought StochRSI and proximity to resistance increase risk of pullback.",
"Low volume (RVOL 0.00x) suggests absence of strong momentum confirmation."
],
"news_summary": "Web search on 2026-08-11 confirms the Euro Stoxx 50 is in an uptrend, trading above its 200-day moving average with strong buy signals from multiple moving averages ([investing.com](https://ca.investing.com/indices/eu-stoxx50-technical)). Forecast models indicate range-bound behavior with expected moves of ±1.8% over 14 days and no directional clarity ([sigmanomics.com](https://sigmanomics.com/index-markets/euro-stoxx-50)). No earnings or major scheduled catalysts were found for the index within the holding window."
}
ADBE
Confidence: 35/100
Key Levels
- Resistance: $273.13, $275.44
- Support: $241.23, $210.88, $190.12
Rationale
ADBE is in a mixed/consolidating phase, with price at the 10-day high (273.13) and just below the 200 SMA (274.13). The stock has rallied ~20% from the recent low, RSI(14)=69 (near overbought), StochRSI and Bollinger %B are elevated, and 1-hour RSI is 70.8. Reward:risk is unfavorable: a long near resistance offers only ~0.9% upside to next resistance while a stop below the nearest structural level (e.g., 265) would risk ~3% – a reward:risk <0.3. A short is not justified because the daily trend is not bearish (Supertrend up, positive MACD histogram) and there is no confirmed reversal setup. Earnings on Sep 10, 2026 are outside the 10-day window, so gap risk is low, but no reliable trade setup exists at these levels.
Risks
- Price is at strong resistance (273.13) with a low-volume rally, making a breakout unlikely to sustain.
- RSI and StochRSI are overbought, increasing the probability of a pullback.
- If a breakout occurs, entry would be late and reward:risk remains poor.
- No confirmed direction in daily trend; ADX (21.8) shows no strong trend.
News Summary
Next earnings is Sep 10, 2026, well outside the 10-day holding window. Recent news indicates CFO Dan Durn resigned in June 2026 and CEO transition is pending, but no new catalysts are within the next 10 days. Technical data shows a consolidation with price near resistance.
{
"ticker": "ADBE",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 35,
"holding_period_days": null,
"key_levels": {
"support": [
241.23,
210.88,
190.12
],
"resistance": [
273.13,
275.44
]
},
"rationale": "ADBE is in a mixed/consolidating phase, with price at the 10-day high (273.13) and just below the 200 SMA (274.13). The stock has rallied ~20% from the recent low, RSI(14)=69 (near overbought), StochRSI and Bollinger %B are elevated, and 1-hour RSI is 70.8. Reward:risk is unfavorable: a long near resistance offers only ~0.9% upside to next resistance while a stop below the nearest structural level (e.g., 265) would risk ~3% – a reward:risk <0.3. A short is not justified because the daily trend is not bearish (Supertrend up, positive MACD histogram) and there is no confirmed reversal setup. Earnings on Sep 10, 2026 are outside the 10-day window, so gap risk is low, but no reliable trade setup exists at these levels.",
"risks": [
"Price is at strong resistance (273.13) with a low-volume rally, making a breakout unlikely to sustain.",
"RSI and StochRSI are overbought, increasing the probability of a pullback.",
"If a breakout occurs, entry would be late and reward:risk remains poor.",
"No confirmed direction in daily trend; ADX (21.8) shows no strong trend."
],
"news_summary": "Next earnings is Sep 10, 2026, well outside the 10-day holding window. Recent news indicates CFO Dan Durn resigned in June 2026 and CEO transition is pending, but no new catalysts are within the next 10 days. Technical data shows a consolidation with price near resistance."
}